

Increases in Kratom-Related Reports to Poison Centers — National Poison Data System, United States, 2015–2025

Eleanor Blair Towers, PhD^{1,2}; Ynhi T. Thomas, MD^{3,4}; Christopher P. Holstege, MD¹; Rita Farah, PhD¹

Abstract

Kratom, the leaves of a tropical evergreen tree (*Mitragyna speciosa*), is traditionally consumed in Southeast Asia for pain relief, mood enhancement, and to relieve symptoms of opioid withdrawal. Kratom contains psychoactive compounds that interact with opioid receptors and is widely available in various forms in the United States. Its evolution from natural leaf to high-potency alkaloid products has raised concerns about toxicity. Data on kratom-related use that resulted in a report to the National Poison Data System (NPDS) (i.e., kratom exposure report) during 2015–2025 were analyzed to assess trends by exposure report type, demographic characteristics of persons exposed, and outcomes. During the past 11 years, poison centers received a total of 14,449 kratom exposure reports; the record high 3,434 reports in 2025 represent an increase of approximately 1,200% compared with the 258 reports in 2015. Most reports involved males and young adults aged 20–39 years, but reports among adults aged 40–59 years increased most sharply, with rates nearly overlapping with those among young adults by 2025. Although single-substance exposure reports accounted for most reports (62%), multiple-substance reports occurred at higher rates (range = 467–5,442 per 1 million multiple-substance drug exposure reports versus 388–4,045 per 1 million single-substance drug exposure reports), were associated with more hospitalizations (44%–56% versus 24%–29% annually) and serious (life threatening, pronounced, prolonged, or systemic) outcomes (57%–66% versus 41%–49% annually), and accounted for the vast majority of kratom-associated deaths during the study period (184 of 233; 79%). NPDS data indicate that kratom-related reports to poison centers are increasing and expanding among demographic groups, underscoring the value of ongoing surveillance to identify

high-risk patterns of kratom use and guide strategies to reduce risks from multiple-substance exposure reports.

Introduction

Kratom (*Mitragyna speciosa*), a Southeast Asian botanical, was historically consumed as crushed or brewed leaves for pain relief, mood enhancement, and to relieve opioid withdrawal symptoms (1,2). In the United States, kratom has shifted from these traditional preparations to a rapidly expanding commercial market of powders, tablets, gummies, and concentrated energy shots (3). This shift includes availability of high-potency products enriched with isolated kratom alkaloids, particularly 7-hydroxymitragynine, a μ -opioid receptor agonist that is marketed as kratom but is distinct from traditional kratom leaf preparations (4), prompting the [Food and Drug Administration \(FDA\)](#) to call for regulatory action focused on these products. Characterizing national patterns of kratom-related exposure reports can identify patterns of kratom exposures and determine which demographic groups are at highest risk for adverse effects. National Poison Data System (NPDS) data were analyzed to examine trends in kratom-related exposure reports, stratified by exposure report type (single- and multiple-substance exposure reports), demographic characteristics (i.e., age and sex), and medical outcomes.

INSIDE

146 [Vaccination Coverage by Age 24 Months Among Children Born in 2021 and 2022 — National Immunization Survey-Child, United States, 2022–2024](#)

[Continuing Education examination available at https://www.cdc.gov/mmw/mmwwr_continuingEducation.html](https://www.cdc.gov/mmw/mmwwr_continuingEducation.html)



U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE
CONTROL AND PREVENTION

Methods

Data Source and Study Period

Kratom exposure report data were extracted from NPDS, the data repository for 53 U.S. poison centers, for January 1, 2015–December 31, 2025. Each poison center submits, in near real-time, deidentified case data to NPDS after providing necessary poison exposure management and information services. The NPDS coding manual defines an exposure report as actual or suspected contact with a substance that prompted a consultation with a poison center, regardless of toxicity or clinical manifestations.

Study Design and Case Identification

To align with the age groups used in the [National Survey on Drug Use and Health](#), the primary U.S. substance use surveillance system, investigators queried NPDS for kratom exposure reports among persons aged ≥ 12 years. Both single-substance exposure reports (kratom as the only reported substance) and multiple-substance exposure reports (kratom and other substances reported for the same exposure) were included. No cases were excluded. Data on patient demographic characteristics (age and sex), exposure (substances and reported reason for use), level of care received, and medical outcome were included.

Data Analysis

Data were analyzed by age group (12–19, 20–39, 40–59, and ≥ 60 years). Serious outcomes included exposures that resulted in death, major effects, and moderate effects.* Kratom-associated hospitalization was defined as an exposure that resulted in hospital admissions to critical care, noncritical care, or psychiatric units. For multiple-substance exposure reports, other substances were described by therapeutic class.† Total kratom exposure report rates were calculated per 1 million drug exposure reports, single-substance kratom exposure report rates were calculated per 1 million single-substance drug exposure reports, and multiple-substance kratom exposure report rates

* The medical outcome is the final determination made by the specialist in poison information, based upon all the information available at the conclusion of the case. NPDS defines major effects as life threatening or resulting in significant disability or disfigurement (e.g., status epilepticus). Moderate effects are pronounced, prolonged, or systemic and usually require some form of treatment, but are not life threatening (e.g., hypoglycemia with confusion). Minor effects are minimally bothersome and resolve rapidly (e.g., sinus tachycardia without hypotension). No effect is reserved for patients who develop no symptoms as a result of the exposure.

† Therapeutic classes included antidepressants (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and other or unspecified antidepressants), stimulants (amphetamines and related compounds, cocaine, methamphetamine, methylphenidate, synthetic cathinones, synthetic phenethylamines, and other or unknown stimulants), cannabis and cannabinoid products (plant material, concentrates, edible products, cannabidiol, synthetic cannabinoids, and minor cannabinoids), and opioids (prescription opioids, heroin, buprenorphine, fentanyl, tramadol, and opioid combination products).

The *MMWR* series of publications is published by the Office of Science, U.S. Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

Suggested citation: [Author names; first three, then et al., if more than six.] [Report title]. *MMWR Morb Mortal Wkly Rep* 2026;75:[inclusive page numbers].

U.S. Centers for Disease Control and Prevention

Jay Bhattacharya, MD, PhD, *Acting Director*
Althea Grant-Lenzy, PhD, *Acting Director, Office of Science*

MMWR Editorial and Production Staff (Weekly)

Leonard Jack, Jr, PhD, MSc, *Acting Editor in Chief*

Terraye M. Starr,
Acting Lead Health Communication Specialist
Alexander J. Gottardy,
Maureen A. Leahy, Armina Velarde,
Visual Information Specialists
Quang M. Doan, MBA,
Phyllis H. King, Moua Yang,
Information Technology Specialists

Kiana Cohen, MPH,
Leslie Hamlin, Lowery Johnson,
Health Communication Specialists
Will Yang, MA,
Visual Information Specialist

Jacqueline Gindler, MD, *Editor*
Mary Dott, MD, MPH, *Online Editor*
Terisa F. Rutledge, *Managing Editor*
Catherine B. Lansdowne, MS,
Acting Lead Technical Writer-Editor
Stacy Simon, MA, Morgan Thompson,
Suzanne Webb, PhD, MA,
Technical Writer-Editors

MMWR Editorial Board

Matthew L. Boulton, MD, MPH
Carolyn Brooks, ScD, MA
Virginia A. Caine, MD
Jonathan E. Fielding, MD, MPH, MBA

Timothy F. Jones, MD, *Chairman*
David W. Fleming, MD
William E. Halperin, MD, DrPH, MPH
Jewel Mullen, MD, MPH, MPA
Jeff Niederdeppe, PhD
Patricia Quinlisk, MD, MPH

Patrick L. Remington, MD, MPH
Carlos Roig, MS, MA
William Schaffner, MD
Morgan Bobb Swanson, MD, PhD

were calculated per 1 million multiple-substance drug exposure reports. Analyses were stratified by exposure report type, sex, and age. Year-to-year changes in exposure report rates were examined using an exact two-sample Poisson rate-ratio test. The Benjamini–Hochberg procedure was used to adjust for multiple comparisons. The study was conducted using deidentified and publicly available data. The University of Virginia Institutional Review Board determined the research on deidentified and publicly available data did not require human subjects review.

Results

Exposure Report Trends

During 2015–2025, U.S. poison centers documented 14,449 kratom exposures; the 3,434 exposures reported in 2025 represent an increase of approximately 1,200% compared with the 258 reported in 2015 (Figure 1). Exposure report rates increased in parallel with the number of exposure reports, from 412 to 4,445 per 1 million drug exposure reports, with a steady increase through 2019, a plateau during 2020–2024, and a marked surge in 2025 that exceeded all previous years (2,171 per 1 million drug exposure reports in 2024 compared with 4,445 per 1 million drug exposure reports in 2025) (Supplementary Table 1). During the 11-year study period, multiple-substance exposure reports (5,513), accounted for 38% of all kratom-associated exposure reports. Annual rates of multiple-substance exposure reports consistently exceeded rates of single-substance exposure reports (by 18%–81%); the 2025 rate of 5,442 per 1 million multiple-substance drug exposure reports was approximately 10 times higher than that in 2015 (467). The single-substance exposure report rate in 2025 (4,045 per 1 million single-substance drug exposure reports) was approximately nine times higher than the rate in 2015 (388).

Analyses by quarterly intervals demonstrated patterns similar to those observed in annual data (Supplementary Figure). The most common substances involved in multiple-substance exposure reports across this study period were addictive substances (ethanol, 22%; opioids, 16%; benzodiazepines, 15%; cannabis and cannabinoids, 12%; and stimulants, 11%) and antidepressants (14%).

Demographic Characteristics of Persons with Kratom Exposure Reports

During the study period, males accounted for the highest percentages of reported kratom-associated exposure reports (range = 65%–71% of single-substance and 67%–76% of multiple-substance exposure reports annually) and higher exposure report rates: 2025 rates of single-substance exposure among males (7,955 per million single-substance drug exposure

Summary

What is already known about this topic?

Kratom (*Mitragyna speciosa*), a plant used for its psychoactive properties, is widely available in the United States. The recent shift from traditional leaf preparations to high-potency alkaloid extracts has raised safety concerns.

What is added by this report?

Analysis of 2015–2025 National Poison Data System data found an increase of approximately 1,200% in kratom-related exposure reports (from 258 to 3,434), including a marked surge in 2025. Multiple-substance exposure reports, often involving addictive substances and antidepressants, were linked to the most severe clinical outcomes.

What are the implications for public health practice?

Kratom use remains a public health concern. Ongoing surveillance could help to identify high-risk patterns of use and guide public health education and clinical care, particularly for multisubstance use.


reports) were 10 times higher than were those in 2015 (709), and multiple-substance rates in 2025 (9,945 per million multiple-substance drug exposure reports) were 11 times higher than were those in 2015 (825) (Figure 2). Among females, single-substance exposure reports rates in 2025 (1,937 per million single-substance drug exposure reports) were nine times higher than were rates in 2015 (190) and multiple-substance exposure report rates in 2025 (2,664 per million multiple-substance drug exposure reports) were 10 times higher than were those in 2015 (239).

Level of Care and Medical Outcome

Hospitalizations for single-substance kratom exposure reports increased 1,200%, from 43 in 2015 to 538 in 2025, and for multiple-substance exposure reports, increased 1,300%, from 40 to 549 (Figure 3). The annual percentage of hospitalizations was consistently higher among persons with multiple-substance exposure reports (44%–56%) than among those with single-substance exposure reports (24%–29%).

A similar pattern was observed for serious outcomes, which increased 1,100% for single-substance (from 76 in 2015 to 919 in 2025) and 1,300% for multiple-substance exposures reports (from 51 in 2015 to 725 in 2025), with consistently higher annual rates reported for multiple-substance exposure reports (57%–66%) than for single-substance exposure reports (41%–49%). Among 233 kratom-associated deaths reported during 2015–2025, which accounted for 3.2% of all 7,287 serious medical outcomes, 184 (79%) involved multiple substances. Opioids were reported in 62% of fatalities, followed by benzodiazepines (20%), stimulants (20%), and ethanol (19%) (Supplementary Table 2).

FIGURE 1. Frequency and rate* of kratom-related exposure reports to poison centers among persons aged ≥12 years, overall (A)[†] and by single- or multiple-substance exposure report (B)[§] — National Poison Data System, United States, 2015–2025



* Single-substance and multiple-substance kratom exposure reports per 1 million reported single-drug and multiple-drug exposure reports, respectively.
[†] Year-to-year rates were significantly different during 2015–2018, 2020–2022, and 2024–2025.
[§] Year-to-year rates were significantly different for single-substance exposure reports (kratom as the only substance reported) during 2015–2018 and 2023–2025 and multiple-substance exposures (kratom and another substance reported for the same exposure) during 2015–2018, 2020–2023, and 2024–2025.

Reason for Exposure Report


Intentional misuse was the most commonly reported reason for exposure report (56% of single-substance and 49% of multiple-substance exposure reports). Suspected suicide attempts were more frequent among persons with multiple-substance exposure reports (23%) than single-substance exposure reports (6%) ([Supplementary Table 2](#)).

Discussion

During 2015–2025, kratom-related exposures reported to NPDS increased by approximately 1,200%, reaching

record levels in 2025. Both single- and multiple-substance exposure reports increased during 2015–2019; thereafter, multiple-substance exposure reports continued to rise modestly through 2024, whereas single-substance exposure reports largely plateaued, with both increasing sharply in 2025. The large increase in 2025 coincides with the emergence of high-potency, semisynthetic formulations, including 7-hydroxymitragynine (4). National survey data among persons aged ≥12 years demonstrate that although annual kratom use prevalence was stable from 2019 to 2023, lifetime use increased from 4 million to 5 million persons, indicating

FIGURE 2. Rates* of kratom-related single- and multiple-substance exposure reports to poison centers among persons aged ≥ 12 years, by sex (A)^{†,§} and age group (B)^{¶,} — National Poison Data System, United States, 2015–2025**



* Single-substance and multiple-substance kratom exposure reports per 1 million reported single-drug and multiple-drug exposure reports, respectively.

[†] Year-to-year rates were significantly different for single-substance exposure reports among males during 2015–2018, 2020–2022, 2023–2024, and 2024–2025 and among females during 2015–2018, 2019–2020, and 2024–2025.

[§] Year-to-year rates were significantly different for multiple-substance exposure reports among males during 2015–2018, 2020–2022, and 2024–2025 and among females during 2015–2016, 2017–2018, 2022–2023, and 2024–2025.

[¶] Year-to-year rates were significantly different for single-substance exposure reports among adolescents aged 12–19 years during 2017–2018 and 2024–2025; among adults aged 20–39 years during 2015–2018, 2021–2022, and 2024–2025; among adults aged 40–59 years during 2015–2016, 2017–2018, 2020–2021, and 2023–2025; and among adults aged ≥ 60 years during 2016–2018 and 2024–2025.


^{**} Year-to-year rates were significantly different for multiple-substance exposure reports among adolescents aged 12–19 years during 2017–2018 and 2024–2025; among adults aged 20–39 years during 2015–2018, 2020–2022, and 2024–2025; among adults aged 40–59 years during 2015–2016, 2017–2018, 2019–2021, and 2024–2025; and among adults aged ≥ 60 years during 2024–2025.

that more persons are trying kratom (5). FDA import data further demonstrate record-high demand, as evidenced by 2025 FDA Import Alert 54–15, which addressed the high volume of kratom-containing products entering the United States (6). Consistent with these trends, this analysis found sharp increases in exposure reports among adults aged 40–59 years, with rates nearly matching those in persons aged 20–39 years. Together, these findings indicate that kratom use is increasing and expanding across demographic groups, underscoring a growing public health concern. In 2025, among all multiple-substance exposure reports, 60% resulted in serious medical outcomes and approximately one half required hospitalization. Enhanced surveillance and public health education could be beneficial given kratom's widespread availability, lack of regulation, minimal medical oversight, and involvement in high-risk multisubstance exposures.

The findings in this report describe the impact of the rapidly evolving kratom market and highlight the important role poison centers can play as an early warning surveillance

system to detect new trends and guide community partners, including clinicians, members of the public, and public health leadership. Severe outcomes were observed among persons who used kratom with other substances: approximately one half required inpatient hospitalization, and 79% of reported kratom-associated deaths involved multiple substances. Kratom use with alcohol, opioids, benzodiazepines, stimulants, and antidepressants might increase risk through additive pharmacodynamic effects on central nervous system pathways and through pharmacokinetic interactions that increase systemic exposure to substances used with kratom (1,2,7). This concern is heightened by the emergence of semisynthetic kratom products that have higher affinity for the opioid receptor, given that the majority of deaths involved kratom use with opioids (4). Psychiatric comorbidity might also compound harm. Previous studies indicate that approximately one third of kratom users met criteria for another substance use disorder (8), and approximately two thirds reported using kratom to manage depression or anxiety (9). Consistent with

FIGURE 3. Frequency and percentage of kratom exposure reports resulting in critical care, noncritical care, or psychiatric hospitalization (A), serious medical outcomes* (B), and death (C) among persons aged ≥ 12 years reported to poison centers, by single- or multiple-substance exposure — National Poison Data System, United States, 2015–2025†



* Serious medical outcomes were defined as exposures resulting in death, major outcomes (those that are life-threatening or result in significant disability or disfigurement), or moderate outcomes (those that are pronounced, prolonged, or systemic, and usually require some form of treatment, but are not life-threatening), per [National Poison Data System definitions](#).

† Y-axis scales differ across panels.

these findings, suicide attempts accounted for approximately one fourth of multiple-substance exposure reports, compared with only 6% of single-substance exposure reports, and antidepressants were involved in 14% of multiple-substance exposure reports, underscoring a connection between kratom use and mental health crises.

Limitations

The findings in this report are subject to at least four limitations. First, NPDS relies on voluntary, self-reported data that might result in an underestimate of the number of milder events. Second, the poison center reports included reports from repeat callers, and certain substances or outcomes might have been misclassified despite standardized procedures. Third, the data do not include information about whether the kratom use involved traditional leaf products or semisynthetic or concentrated formulations, such as 7-hydroxymitragynine, thereby limiting conclusions about formulation-specific risks. Finally, multiple substances can be reported for each exposure report, and determining which substance was most related to clinical effects or medical outcome, including death, was not possible.

Implications for Public Health Practice

Kratom-related adverse effects are increasing in number and complexity in the United States. Increasing use, the availability of high-potency kratom, and frequent multiple-substance exposure reports contribute to hospitalizations from physical as well as psychiatric causes. As FDA moves to regulate 7-hydroxymitragynine but not whole-leaf kratom products, surveillance should distinguish product types to assess risks (10). Building this evidence base is essential to promoting safe kratom use, identifying high-risk combinations of substances, and guiding public health action to prevent future health effects in this rapidly evolving drug landscape.

Corresponding author: Christopher P. Holstege, ch2xf@uvahealth.org.

¹Department of Emergency Medicine, Division of Medical Toxicology, University of Virginia, Charlottesville, Virginia; ²Medical Scientist Training Program, University of Virginia, Charlottesville, Virginia; ³Henry J.N. Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, Texas; ⁴Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, Texas.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Ynhi T. Thomas reports receipt of support from the Food and Drug Administration through a cooperative agreement for a human abuse potential study of kratom, outside the submitted

work. Eleanor Blair Towers reports receipt of a Medical Scientist Training Program grant and a Pharmacological Science Training grant from the University of Virginia, an International Study Group Investigating Drugs as Reinforcers travel award, an American College of Neuropsychopharmacology travel award, a Jevtovic-Todorovic travel award, a National Institute on Drug Abuse travel award, and a College on Problems of Drug Dependence Women & Sex/Gender Junior Investigator travel award. No other potential conflicts of interest were disclosed.

References

1. Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. *J Am Osteopath Assoc* 2012;112:792–9. PMID:23212430
2. Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. *Neuropharmacology* 2018;134(Pt A):108–20. PMID:28830758 <https://doi.org/10.1016/j.neuropharm.2017.08.026>
3. Glover M. The marketing of self-care and alternative therapies in the U.S. in 2019: how industry stakeholders appeal to consumers' perceptions of novel food products and additives. *J Food Law Policy* 2020;15. <https://doi.org/10.54119/jflp.rvjg5570>
4. Alsbrook S, Pro G, Koturbash I. From kratom to 7-hydroxymitragynine: evolution of a natural remedy into a public-health threat. *Pharm Biol* 2025;63:896–911. PMID:41275505 <https://doi.org/10.1080/13880209.2025.2590311>
5. Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health (NSDUH): key resources and tools for NSDUH. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2025. Accessed July 27, 2025. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health>
6. US Food and Drug Administration. Import Alert 54–15: detention without physical examination of dietary supplements and bulk dietary ingredients that are or contain kratom (*Mitragyna speciosa*). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2026. https://www.accessdata.fda.gov/cms_ia/importalert_1137.html
7. Dhoble LR, Gour A, McCurdy CR, Sharma A. Evaluating the drug interactions in kratom usage: clinical application. *Expert Opin Drug Metab Toxicol* 2025;21:949–59. PMID:40522665 <https://doi.org/10.1080/17425255.2025.2521045>
8. Xu KY, Mintz CM, Borodovsky JT, Glaser PEA, Bierut L, Gruzca RA. Prevalence of kratom use and co-occurring substance use disorders in the United States. *Prim Care Companion CNS Disord* 2021;23:21br02930. PMID:34352941 <https://doi.org/10.4088/pcc.21br02930>
9. Grundmann O. Patterns of Kratom use and health impact in the US—results from an online survey. *Drug Alcohol Depend* 2017;176:63–70. PMID:28521200 <https://doi.org/10.1016/j.drugalcdep.2017.03.007>
10. US Food and Drug Administration. FDA takes steps to restrict 7-OH opioid products threatening American consumers [Press release]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2026. <https://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers>

Vaccination Coverage by Age 24 Months Among Children Born in 2021 and 2022 — National Immunization Survey-Child, United States, 2022–2024

Holly A. Hill, MD, PhD¹; David Yankey, PhD¹; Laurie D. Elam-Evans, PhD¹; Yi Mu, PhD¹; Michael Chen, PhD¹; Shannon Stokley, DrPH¹; Georgina Peacock, MD¹; James A. Singleton, PhD¹

Abstract

The National Immunization Survey-Child monitors coverage with recommended routine childhood vaccines. For data collected in survey year 2024, which include children born in 2021 and 2022, the household response rate (23.4%) and availability of adequate provider data for children with completed interviews (51.4%) were comparable to those from earlier survey years. For most vaccines, coverage by age 24 months was similar among children born in 2021 and 2022 and those born in 2019 and 2020. Declines in coverage of 1–2 percentage points were observed for the primary series of *Haemophilus influenzae* type b conjugate vaccine, the birth dose of hepatitis B vaccine, ≥ 4 doses of pneumococcal conjugate vaccine, and rotavirus vaccine. Coverage with ≥ 2 doses of influenza vaccine by age 24 months decreased from 61.0% among children born during 2019–2020 to 53.5% among those born during 2021–2022. Coverage was lower among Vaccines for Children (VFC) program–eligible children than among those who were not VFC-eligible and differed substantially by jurisdiction. Compared with non-Hispanic White children, coverage with many vaccines was lower among non-Hispanic Black or African American and Hispanic or Latino children; coverage was highest among non-Hispanic Asian children. Coverage was also lower among children living in poverty and those living in more rural areas. Maintaining high levels of vaccination and improving coverage among groups and in areas in which rates have declined could help protect children from vaccine-preventable morbidity and mortality. The Community Preventive Services Task Force recommends several interventions to increase vaccination, including standing orders for vaccination, immunization information systems, and vaccination programs in organized child care centers and in Special Supplemental Nutrition Program for Woman, Infants, and Children settings. Other factors demonstrated to be effective include strong provider recommendations, targeted messages from credible and trusted sources, and increased participation in the VFC program.

Introduction

As a public health strategy, immunization of young children has been critical to reducing morbidity and mortality due to vaccine-preventable diseases and has been found to be

highly cost effective (1). During 2024, the most recent year of data collection available for this report, U.S. vaccination recommendations included receipt of routine vaccines and a monoclonal antibody to protect children against 16 potentially dangerous infections by age 24 months (2). For approximately 30 years, coverage with recommended childhood vaccines has been monitored by the [National Immunization Survey-Child \(NIS-Child\)](#).^{*} Data from NIS-Child are used to estimate coverage at national, regional, state, and selected local area levels and for three U.S. territories (Guam, Puerto Rico, and the U.S. Virgin Islands).[†] Data are stratified by the child's year of birth, and vaccination status by age 24 months (or other milestone age) is assessed. This report describes trends in national coverage with recommended vaccines over time (excluding COVID-19 vaccine)[§] and provides coverage estimates by [Vaccines for Children \(VFC\)](#) program eligibility,[¶] race and ethnicity, poverty status, urbanicity, and jurisdiction of residence.

^{*} Immunization against respiratory syncytial virus (RSV) using nirsevimab was recommended in August 2023 for infants aged <8 months born during or entering their first RSV season and for infants and children aged 8–19 months who are at increased risk for severe RSV disease and entering their second RSV season. Estimates of nirsevimab coverage are not provided in this report because 1) the first cohort of eligible children was born April 2023–March 2024, but only a small number of children in NIS-Child in 2024 were born during this period, and 2) NIS-Child did not collect data on high-risk conditions in 2024; therefore, assessment of coverage among those who are eligible for nirsevimab during their second RSV season at age 8–19 months was not possible. Another monoclonal antibody, clesrovimab, has been recommended since June 2025, for infants aged <8 months born during or entering their first RSV season who are not protected by maternal vaccination. No preferential recommendation exists between nirsevimab and clesrovimab.

[†] Vaccination coverage is calculated nationally and for U.S. Department of Health and Human Services regions, states (including the District of Columbia), selected local areas, and the U.S. territories of Guam, Puerto Rico, and the U.S. Virgin Islands (sampled every other year; data were not collected in 2020, 2022, or 2024). Certain local areas that receive federal Section 317 immunization funds are sampled separately and included in the NIS-Child sample every year (i.e., Chicago, Illinois; New York, New York; Philadelphia County, Pennsylvania; Bexar County, Texas; and Houston, Texas). National estimates in this report exclude U.S. territories.

[§] Estimates of COVID-19 vaccination coverage are not included in this report. More timely estimates are available online. [COVID-19 Vaccination Coverage and Vaccine Confidence Among Children | COVIDVaxView | CDC](#)

[¶] VFC eligibility was defined as meeting at least one of the following criteria: 1) American Indian or Alaska Native; 2) insured by Medicaid, Indian Health Service, or uninsured; or 3) ever having received at least one vaccination at an Indian Health Service–operated center, Tribal health center, or urban Indian health care facility. The VFC program provides free vaccines to eligible children for whom cost might otherwise be a barrier to vaccination.

Methods

Data Collection

U.S. households that include children aged 19–35 months are identified through random-digit-dialing and invited to participate in NIS-Child. Household interviews with the adult most knowledgeable about the child's vaccination history (usually a parent) are conducted via cellular telephone,** and consent is requested to contact the child's vaccination providers and the state immunization registry. Once consent is obtained, a questionnaire is mailed to all of the child's providers requesting detailed information about vaccines received by the child since birth. This information is synthesized into a comprehensive vaccination history for each child, which then serves as the basis for the coverage estimates included in this report.

Among households with eligible children identified in 2024 (the most recent survey year available), the household interview response rate^{††} was 23.4%, and adequate provider data^{§§} were available for 51.4% of children with completed interviews. NIS-Child uses a complex weighting process that includes adjustments for household nonresponse, provider nonresponse, and households without cellular telephones. Weights are calibrated to known population totals by age, sex, race and ethnicity, and geography to improve representation. Nonresponse adjustments are incorporated in the weighting to reduce potential bias. In addition, statistical modeling techniques such as imputation and variance estimation methods are used to handle missing data and account for the complex survey design ([NIS-Child: A User's Guide](#)). Children born during 2021–2022 were identified from data collected during survey years 2022–2024; data from 27,392 children were available for analysis. Application of survey weights to

reflect the complex sample design of NIS-Child resulted in a weighted total sample size of 7,454,623.

Data Analysis

Data from multiple survey years were combined and then stratified by year of birth to create birth cohorts for analysis. Kaplan-Meier techniques were used to estimate vaccination coverage by age 24 months for most vaccines. Exceptions include the birth dose of hepatitis B vaccine (HepB), which is considered received if administered during the first 3 days of life, and the rotavirus vaccine series, which is not meant to be given after age 8 months, 0 days. Because of a change in vaccination recommendations in 2020 and a long period of eligibility for catch-up vaccination, coverage with ≥ 2 doses of hepatitis A vaccine (HepA) was estimated by age 35 months (the maximum age within the scope of NIS-Child data collection) as well as by age 24 months.^{¶¶} Differences in coverage estimates were evaluated using z-tests at an α -level of 0.05. Estimated coverage nationally and by jurisdiction among children born during 2021 and 2022 was compared with that among children born during 2019 and 2020. For data stratified by sociodemographic characteristics, subgroup estimates were compared with those for a designated referent group. Analyses used weighted data and were performed using SAS software (version 9.4; SAS Institute) and SUDAAN software (version 11; RTI International). This activity was reviewed by CDC, deemed not research, and was conducted consistent with applicable federal law and CDC policy.^{***}

Results

Recent Trends in National Vaccination Coverage by Birth Year

The largest difference in estimated vaccination coverage by age 24 months between children born in 2021 and 2022 and those born in 2019 and 2020 was a 7.4 percentage point decrease in coverage with ≥ 2 doses of influenza vaccine (Table 1). Smaller decreases were observed in coverage with the birth dose of HepB (1.8 percentage points), rotavirus vaccine (1.7), ≥ 4 doses of pneumococcal conjugate vaccine (PCV) (1.5), and the primary series of *Haemophilus influenzae* type b conjugate vaccine (Hib) (1.0). Nonsignificant decreases were observed for coverage with nearly all of the remaining

** NIS-Child used a landline-only sampling frame during 1995–2010. During 2011–2017, the survey was conducted using a dual-frame design, with both cellular and landline sampling frames included. In 2018, the NIS-Child returned to a single-frame design, with all interviews conducted by cellular telephone. [During 2018–2024, 95%–98% of U.S. adults reported owning a cellular telephone.](#)

†† The Council of American Survey Research Organizations (CASRO) household response rate is calculated as the product of the resolution rate (percentage of the total telephone numbers called that were classified as nonworking, nonresidential, or residential), screening completion rate (percentage of known households that were successfully screened for the presence of age-eligible children), and the interview completion rate (percentage of households with one or more age-eligible children that completed the household survey). CASRO response rates and the proportions of children with household interviews that had adequate provider data for survey years 2015–2023 are available online. [NIS-Child: A User's Guide for the 2023 Public Use Data File](#)

§§ Children with at least one vaccination reported by a provider and those who had received no vaccinations were considered to have adequate provider data. "No vaccinations" indicates that the vaccination status is known because the parent or guardian indicated there were no vaccinations and the providers returned no immunization history forms or returned them indicating that no vaccinations had been administered.

¶¶ Before 2020, the first dose of HepA was recommended at age 12–23 months, with the second dose administered 6–18 months after the first. During 2020, the recommendation was revised to 2 doses administered at age 12–23 months, ≥ 6 months apart, with a catch-up period extending through age 18 years. Because children in this analysis were vaccinated under both recommendations, coverage estimates for both age < 24 months and age < 35 months are provided.

*** 45 C.F.R. part 46.102(l)(2); 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

TABLE 1. Estimated vaccination coverage by age 24 months* among children born during 2019–2020 and 2021–2022 with selected vaccines and doses and percentage point differences in coverage between birth cohorts — National Immunization Survey-Child, United States, 2020–2024

Vaccine/Doses received	Birth years [†] % (95% CI)		Percentage point difference (95% CI)
	2019–2020	2021–2022	2019–2020 to 2021–2022
DTaP [§]			
≥3 doses	93.3 (92.7 to 93.8)	92.7 (92.1 to 93.3)	-0.5 (-1.4 to 0.3)
≥4 doses	80.5 (79.5 to 81.4)	80.7 (79.7 to 81.6)	0.2 (-1.1 to 1.5)
Poliovirus (≥3 doses)	92.5 (91.9 to 93.0)	92.1 (91.5 to 92.8)	-0.3 (-1.2 to 0.5)
MMR (≥1 dose) [¶]	90.9 (90.2 to 91.5)	90.8 (90.1 to 91.5)	0 (-1.0 to 0.9)
Hib ^{**}			
Primary series	92.9 (92.3 to 93.4)	91.9 (91.2 to 92.5)	-1.0 (-1.8 to -0.1) ^{††}
Full series	78.8 (77.9 to 79.6)	77.6 (76.6 to 78.5)	-1.2 (-2.5 to 0.1)
HepB			
Birth dose ^{§§}	81.1 (80.3 to 81.8)	79.3 (78.3 to 80.2)	-1.8 (-3.0 to -0.6) ^{††}
≥3 doses	91.8 (91.2 to 92.4)	91.6 (91.0 to 92.3)	-0.1 (-1.0 to 0.8)
VAR (≥1 dose) ^{¶¶}	90.4 (89.7 to 91.1)	90.0 (89.3 to 90.7)	-0.4 (-1.4 to 0.6)
PCV			
≥3 doses	92.3 (91.7 to 92.9)	91.4 (90.8 to 92.1)	-0.9 (-1.7 to 0)
≥4 doses	82.0 (81.2 to 82.9)	80.5 (79.5 to 81.4)	-1.5 (-2.8 to -0.3) ^{††}
HepA ^{¶¶¶}			
≥1 dose	87.6 (86.9 to 88.3)	87.1 (86.3 to 87.8)	-0.5 (-1.6 to 0.5)
≥2 doses	47.5 (46.5 to 48.5)	46.8 (45.7 to 48.0)	-0.6 (-2.1 to 0.9)
≥2 doses (by age 35 mos)	79.3 (78.0 to 80.5)	78.7 (77.3 to 80.1)	-0.5 (-2.4 to 1.3)
Rotavirus (by age 8 mos) ^{***}	75.8 (74.9 to 76.7)	74.2 (73.1 to 75.2)	-1.7 (-3.0 to -0.3) ^{††}
Influenza (≥2 doses) ^{†††}	61.0 (60.0 to 61.9)	53.5 (52.4 to 54.6)	-7.4 (-8.9 to -5.9) ^{††}
Combined 7-vaccine series ^{§§§}	69.1 (68.1 to 70.1)	68.0 (67.0 to 69.1)	-1.0 (-2.5 to 0.4)
No vaccinations ^{¶¶¶¶}	1.2 (1.0 to 1.4)	1.2 (1.0 to 1.5)	0.1 (-0.2 to 0.4)

Abbreviations: DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; VAR = varicella vaccine.

* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by age 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥2 HepA doses).

[†] Data for the 2019 birth year are from survey years 2020, 2021, and 2022; data for the 2020 birth year are from survey years 2021, 2022, and 2023; data for the 2021 birth year are from survey years 2022, 2023, and 2024; and data for the 2022 birth year are considered preliminary and come from survey years 2023 and 2024 (data from survey year 2025 are not yet available).

[§] Includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine. [Healthy People 2030 target for ≥4 doses of DTaP by age 2 years is 90.0%.](#)

[¶] Includes children who might have been vaccinated with measles, mumps, rubella, and varicella combination vaccine. [Healthy People 2030 target for ≥1 dose of MMR by age 2 years is 90.8%.](#)

^{**} Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.

^{††} Statistically significantly different ($p < 0.05$) from zero (z-test).

^{§§} One dose of HepB administered from birth through age 3 days.

^{¶¶} In 2020, the HepA recommendation was revised to 2 doses at age 12–23 months, ≥6 months apart, with catch-up vaccination extending to age 18 years. Because of the prolonged eligibility period, coverage estimates for both age <24 months and age <35 months are provided.

^{***} Includes ≥2 doses of Rotarix monovalent rotavirus vaccine, or ≥3 doses of RotaTaq pentavalent rotavirus vaccine. (If any dose in the series is either RotaTaq or unknown, the recommendation defaults to the 3-dose series.) The maximum age for the final rotavirus dose is 8 months, 0 days.

^{†††} Doses must be ≥24 days apart (4 weeks with a 4-day grace period); doses could have been received during two influenza seasons.

^{§§§} The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of VAR, and ≥4 doses of PCV.

^{¶¶¶¶} [Healthy People 2030 target for children who receive no recommended vaccines by age 2 years is ≤1.3%.](#)

vaccines. Coverage remained at or above 90.0% for ≥3 doses of poliovirus vaccine (92.1%), ≥3 doses of HepB (91.6%), ≥1 dose of measles, mumps, and rubella vaccine (MMR) (90.8%), and ≥1 dose of varicella vaccine (VAR) (90.0%). The lowest estimates of coverage were for ≥2 doses of HepA by age 24 months (46.8%) and ≥2 doses of influenza vaccine (53.5%). The percentage of children who received no vaccinations (1.2%) continued to meet the [Healthy People 2030](#) target of ≤1.3%. Longer term trends (2011–2022) by single-year

birth cohort reveal coverage consistently at or above 90.0% with ≥3 doses of poliovirus vaccine (range = 91.0%–93.8%), ≥1 dose of MMR (range = 89.8%–92.3%), ≥3 doses of HepB (range = 89.8%–92.6%), and ≥1 dose of VAR (range = 89.1%–91.2%) ([Supplementary Figure](#)). Although coverage with the birth dose of HepB increased by 10.6 percentage points during 2014–2019, coverage has steadily declined for the past three birth cohorts. Coverage with ≥2 doses of influenza vaccine declined significantly (12.0 percentage points) since 2019.

Vaccination Coverage by Selected Sociodemographic Characteristics

Coverage with all vaccines was lower among children born in 2021 and 2022 who were eligible for VFC than among those who were not VFC-eligible (Table 2). Differences in coverage ranged from 2.5 percentage points (≥ 3 doses of HepB) to 22.4 percentage points (≥ 2 doses of influenza vaccine). By race and ethnicity, coverage with most vaccines was lower among non-Hispanic Black or African American children than among non-Hispanic White (White) children ([Supplementary Table 1](#)); exceptions include ≥ 1 dose of HepA, ≥ 2 doses of HepA (by age

35 months), the birth dose of HepB, ≥ 3 doses of HepB, and ≥ 1 dose of VAR. Compared with White children, coverage with ≥ 4 doses of diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP) (5.5 percentage points), the full series of Hib (4.0), ≥ 4 doses of PCV (8.9), rotavirus (10.1), ≥ 2 doses of influenza vaccine (6.9), and the combined 7-vaccine series^{†††} (7.1) was lower among Hispanic or Latino children. Coverage with approximately one half of the vaccines assessed was higher

^{†††} The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥ 4 doses of DTaP, ≥ 3 doses of poliovirus vaccine, ≥ 1 dose of measles-containing vaccine, ≥ 3 or ≥ 4 doses (depending upon product type) of Hib, ≥ 3 doses of HepB, ≥ 1 dose of VAR, and ≥ 4 doses of PCV.

TABLE 2. Estimated vaccination coverage by age 24 months* among children born during 2021–2022,[†] by selected vaccines and doses and Vaccines for Children eligibility status[‡] — National Immunization Survey-Child, United States, 2022–2024

Vaccine/Doses received	VFC eligibility status, % (95% CI)		Percentage point difference (95% CI)
	Not eligible (referent) n = 16,469	Eligible n = 10,923	
DTaP [¶]			
≥ 3 doses	94.8 (94.0 to 95.5)	90.7 (89.7 to 91.7)	-4.0 (-5.3 to -2.8)**
≥ 4 doses	85.5 (84.3 to 86.6)	76.0 (74.5 to 77.5)	-9.5 (-11.4 to -7.6)**
Poliovirus (≥ 3 doses)	94.1 (93.2 to 94.8)	90.3 (89.3 to 91.3)	-3.7 (-5.0 to -2.5)**
MMR (≥ 1 dose) ^{††}	92.6 (91.7 to 93.4)	89.2 (88.1 to 90.2)	-3.4 (-4.8 to -2.0)**
Hib ^{§§}			
Primary series	94.0 (93.2 to 94.7)	89.8 (88.8 to 90.8)	-4.2 (-5.5 to -2.9)**
Full series	81.9 (80.7 to 83.0)	73.4 (71.9 to 75.0)	-8.4 (-10.4 to -6.5)**
HepB			
Birth dose ^{¶¶}	81.8 (80.6 to 82.9)	76.9 (75.4 to 78.4)	-4.9 (-6.8 to -3.0)**
≥ 3 doses	92.9 (92.0 to 93.7)	90.4 (89.4 to 91.4)	-2.5 (-3.7 to -1.2)**
VAR (≥ 1 dose) ^{††}	91.8 (90.9 to 92.7)	88.3 (87.1 to 89.4)	-3.5 (-5.0 to -2.1)**
PCV			
≥ 3 doses	93.9 (93.1 to 94.6)	89.1 (88.1 to 90.1)	-4.8 (-6.1 to -3.5)**
≥ 4 doses	87.0 (85.9 to 90.3)	74.3 (72.7 to 75.8)	-12.7 (-12.6 to -10.8)**
HepA ^{***}			
≥ 1 dose	89.4 (89.5 to 91.7)	84.8 (83.5 to 86.0)	-4.6 (-6.3 to -3.1)**
≥ 2 doses	49.3 (47.9 to 50.7)	44.4 (42.6 to 46.3)	-4.9 (-7.2 to -2.6)**
≥ 2 doses (by age 35 mos)	82.9 (81.3 to 84.5)	74.8 (72.5 to 77.1)	-8.1 (-10.9 to -5.3)**
Rotavirus (by age 8 mos) ^{†††}	81.6 (80.5 to 82.8)	67.0 (65.3 to 68.6)	-14.7 (-16.7 to -12.6)**
Influenza (≥ 2 doses) ^{§§§}	64.9 (63.6 to 66.3)	42.5 (40.8 to 44.3)	-22.4 (-24.6 to -20.2)**
Combined 7-vaccine series ^{¶¶¶}	74.2 (72.9 to 75.4)	62.1 (60.4 to 63.8)	-12.0 (-14.1 to -9.9)**
No vaccinations	1.1 (0.8 to 1.6)	1.3 (1.0 to 1.6)	0.1 (-0.3 to 0.6)

Abbreviations: DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; VAR = varicella vaccine; VFC = Vaccines for Children.

* Includes vaccinations received before age 24 months, except for the HepB birth dose, rotavirus vaccination, and ≥ 2 HepA doses by age 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥ 2 HepA doses).

[†] Data for the 2021 birth year are from survey years 2022, 2023, and 2024; data for the 2022 birth year are considered preliminary and come from survey years 2023 and 2024 (data from survey year 2025 are not yet available).

[‡] VFC eligibility was defined as meeting at least one of the following criteria: 1) American Indian or Alaska Native; 2) insured by Medicaid or Indian Health Service, or uninsured; or 3) ever received at least one vaccination at an Indian Health Service–operated center, Tribal health center, or urban Indian health care facility.

[¶] Includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria and tetanus toxoids and pertussis vaccine.

** Statistically significant (p<0.05) difference compared with the referent group.

^{††} Includes children who might have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.

^{§§} Hib primary series: receipt of ≥ 2 or ≥ 3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥ 3 or ≥ 4 doses, depending on product type received.

^{¶¶} One dose HepB administered from birth through age 3 days.

^{***} Before 2020, a first dose of HepA was recommended at age 12–23 months, with the second dose 6–18 months after the first, depending upon the product type received. In 2020, the recommendation was revised to 2 doses at age 12–23 months, ≥ 6 months apart. Because children in this analysis were vaccinated under both recommendations, coverage estimates for both age <24 months and age <35 months are provided.

^{†††} Includes ≥ 2 doses of Rotarix monovalent rotavirus vaccine, or ≥ 3 doses of RotaTeq pentavalent rotavirus vaccine. (If any dose in the series is either RotaTeq or unknown, the recommendation defaults to the 3-dose series.) The maximum age for the final rotavirus dose is 8 months, 0 days.

^{§§§} Doses must be ≥ 24 days apart (4 weeks with a 4-day grace period); doses could have been received during two influenza seasons.

^{¶¶¶} The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥ 4 doses of DTaP, ≥ 3 doses of poliovirus vaccine, ≥ 1 dose of measles-containing vaccine, the full series of Hib (≥ 3 or ≥ 4 doses, depending on product type), ≥ 3 doses of HepB, ≥ 1 dose of VAR, and ≥ 4 doses of PCV.

among non-Hispanic Asian (Asian) children than among White children, with percentage point coverage differences ranging from 2.1 (≥ 3 doses of HepB) to 14.6 (≥ 2 influenza vaccine doses). Asian children were less likely than White children to have received no vaccinations (0.6% versus 1.4%). Coverage with all vaccines was lower among children living below the federal poverty level than among those living at or above the poverty level ([Supplementary Table 2](#)), with percentage point differences ranging from 3.5 (≥ 3 doses of HepB) to 18.1 (rotavirus). Compared with children living in a metropolitan statistical area (MSA)^{§§§} principal city (a measure of urbanicity), coverage with most vaccines was lower among children living in non-MSAs. Coverage among children living in an MSA nonprincipal city was lower (1.9 percentage points) only for ≥ 1 dose of HepA.

Vaccination Coverage by Jurisdiction

Variation in coverage with selected vaccines was also observed by jurisdiction (Table 3), especially for ≥ 2 doses of influenza vaccine, which ranged from 25.2% (Mississippi) to 78.3% (Massachusetts). Coverage with ≥ 2 doses of influenza vaccine among children born during 2021–2022 decreased compared with coverage among children born during 2019–2020 in 30 (54.6%) of 56 states and local areas.

Discussion

For most vaccines monitored by NIS-Child, estimated coverage by age 24 months for children born in 2021 and 2022 was similar to coverage among those born in 2019 and 2020. Healthy People 2030 objectives were met for [\$\geq 1\$ dose of MMR](#) (target $\geq 90.8\%$ versus 90.8% achieved) and [receipt of no vaccinations](#) (target $\leq 1.3\%$ versus 1.2% achieved) but not for [\$\geq 4\$ doses of DTaP](#) (target $\geq 90.0\%$ versus 80.7% achieved). Although coverage with most vaccines has been maintained, the decline in coverage with the HepB birth dose for the past three birth cohorts is a notable trend. The birth dose, recommended within 24 hours of birth, according to the immunization schedule that was in place for all children in this study, serves as a universal safeguard against early hepatitis B virus (HBV) transmission. For infants born to mothers who are hepatitis B surface antigen (HBsAg)–positive, the birth dose, administered together with hepatitis B immune globulin, provides the critical first line of protection against perinatal HBV infection. Without this protection, approximately 90% of U.S. infants born to women who are HBsAg-positive will develop chronic infection with HBV, and approximately 25%

^{§§§} MSA status was determined on the basis of household reported city and county of residence and was grouped into three categories: MSA principal city, MSA nonprincipal city, and non-MSA. MSAs and principal cities were [as defined by the U.S. Census Bureau](#). Non-MSA areas include urban populations not located within an MSA as well as completely rural areas.

Summary

What is already known about this topic?

When data were collected for this report in 2024, U.S. vaccination recommendations included routine vaccines and a monoclonal antibody to protect against 16 diseases among children by age 24 months.

What is added by this report?

Coverage with most vaccines was similar among children born during 2021–2022 and those born during 2019–2020. Decreases were observed for five vaccines. Coverage varied by Vaccines for Children (VFC) program eligibility, race and ethnicity, poverty status, urbanicity, and jurisdiction.

What are the implications for public health practice?

Efforts to improve and maintain high levels of vaccination coverage could help to reduce the morbidity and mortality associated with vaccine-preventable diseases. The Community Preventive Services Task Force recommends interventions such as the use of standing vaccination orders, immunization information systems, and vaccination programs in organized child care centers and in Special Supplemental Nutrition Program for Women, Infants, and Children settings. Other factors demonstrated to be effective include strong provider recommendations, targeted messages from credible and trusted sources, and increased participation in the VFC program.

of them will eventually die from chronic liver disease ([Clinical Overview of Perinatal Hepatitis B | CDC](#)). The HepB birth dose is also an important safety net protecting against HBV infection for infants born to the 12%–16% of pregnant women in the United States who, despite having health insurance and receiving prenatal care, are not tested for HBsAg during their pregnancy (3). [Infection can also be transmitted](#) through contact with blood or fluids from HBV-infected family or community members before infants have the opportunity to complete the 3-dose vaccination series.

A large decline in coverage with ≥ 2 doses of influenza vaccine resulted in its lowest level in more than a decade (51.8%). Vaccination against influenza decreased among children during the COVID-19 pandemic and has not yet recovered to prepandemic levels (4). A recent study among children aged 6 months–17 years reported that 30.9% of children had a parent hesitant about influenza vaccination, with higher prevalences of hesitancy among parents of younger children (5). Common reasons reported by parents for not obtaining an influenza vaccination for their children include a lack of belief that their child would get very sick from influenza (48.2%), concern about vaccine safety and side effects (43.3%), and a perception that the vaccine was not highly effective (37.0%) (4). The lack of concern over severity of influenza is relevant given that during the 2024–25 U.S. influenza season, the cumulative influenza-associated hospitalization rate was the highest since

TABLE 3. Estimated vaccination coverage by age 24 months* among children born during 2021–2022,[†] by selected vaccines and doses, overall and by area[§] — National Immunization Survey-Child, United States, 2022–2024

Area	No.	Vaccine coverage, % (95% CI)							Combined 7-vaccine series***
		MMR [¶] (≥1 dose)	Poliovirus (≥3 doses)	DTaP** (≥4 doses)	HepB ^{††} (birth dose)	HepA (≥2 doses by age 35 mos)	Rotavirus ^{§§}	Influenza ^{¶¶} (≥2 doses)	
United States	27,392	90.8	92.1	80.7	79.3	78.7	74.2	53.5	68.0
		(90.1–91.5)	(91.5–92.8)	(79.7–81.6)	(78.3–80.2)†††	(77.3–80.1)	(73.1–75.2)†††	(52.4–54.6)†††	(67.0–69.1)
HHS Region 1, total	2,580	95.1	95.7	88.9	87.3	89.2	83.1	75.0	80.4
		(93.5–96.4)	(94.1–97.0)	(86.5–91.1)	(85.1–89.1)	(85.5–92.3)	(80.2–85.6)	(72.1–77.9)	(77.6–83.0)
Connecticut	390	95.6	95.5	89.8	88.9	92.8	83.9	72.9	79.9
		(92.5–97.7)	(92.0–97.8)	(85.2–93.4)	(84.5–92.2)	(86.5–96.9)	(77.4–88.8)	(65.9–79.6)†††	(74.2–85.0)
Maine	361	93.4	96.3	82.0	81.6	85.1	79.8	66.9	68.7
		(89.6–96.1)	(93.5–98.1)	(75.4–87.8)	(75.3–86.5)	(76.8–91.6)	(74.5–84.2)	(60.3–73.4)	(62.0–75.2)
Massachusetts	452	94.9	95.2	89.4	88.7	88.8	83.1	78.3	82.5
		(91.8–97.1)	(92.1–97.3)	(85.0–93.0)	(84.8–91.7)	(81.3–94.2)	(78.0–87.3)	(73.5–82.6)	(77.7–86.8)
New Hampshire	354	94.7	96.0	90.0	82.8	89.7	83.4	73.0	80.9
		(91.7–96.9)	(93.4–97.8)	(86.2–93.1)§§§	(76.8–87.6)	(83.6–94.3)§§§	(77.9–87.8)	(67.3–78.4)	(75.9–85.5)
Rhode Island	555	95.4	96.7	90.5	86.5	94.3	83.1	74.0	80.2
		(92.7–97.4)	(94.1–98.4)	(86.7–93.6)	(82.9–89.5)§§§	(82.3–99.1)	(78.9–86.5)†††	(69.2–78.6)†††	(75.9–84.3)
Vermont	468	97.4	97.5	87.1	82.5	81.1	83.5	72.4	80.6
		(94.7–98.9)	(95.0–99.0)	(81.9–91.4)	(78.0–86.3)	(71.9–88.7)	(78.9–87.2)	(66.8–77.7)†††	(75.4–85.2)
HHS Region 2, total	1,463	89.3	90.8	79.4	75.2	69.6	71.8	58.9	63.9
		(86.6–91.6)†††	(88.4–92.9)	(76.0–82.7)	(71.7–78.4)†††	(64.5–74.6)†††	(68.4–75.0)	(55.3–62.5)†††	(60.3–67.5)
New Jersey	463	87.7	90.6	77.9	79.7	70.7	72.7	59.2	61.3
		(82.8–91.8)†††	(86.5–93.8)	(71.0–84.1)	(72.7–85.2)	(61.6–79.2)	(66.6–78.1)	(52.6–65.9)†††	(54.6–68.1)
New York	1,000	90.1	90.9	80.2	72.8	69.0	71.3	58.7	65.3
		(86.8–92.9)	(87.8–93.5)	(76.3–83.8)	(68.7–76.6)†††	(62.7–75.0)	(67.1–75.1)†††	(54.5–62.9)†††	(61.1–69.4)
New York City	552	89.3	91.1	80.3	74.4	71.6	73.2	61.6	67.6
		(85.3–92.6)	(87.5–94.0)	(75.4–84.7)	(69.2–78.9)	(63.9–79.0)	(68.1–77.8)	(56.3–67.0)	(62.5–72.7)
New York, excluding New York City	448	90.8	90.8	80.1	71.6	66.2	69.7	56.3	63.4
		(85.4–94.8)	(85.7–94.6)	(74.2–85.5)	(65.2–77.2)	(56.9–75.3)	(63.3–75.4)†††	(50.1–62.6)	(57.2–69.6)
HHS Region 3, total	3,790	91.6	92.9	82.3	81.2	82.1	80.6	61.2	71.5
		(90.0–92.9)	(91.5–94.2)	(80.2–84.3)	(78.9–83.3)	(78.7–85.3)	(78.5–82.5)	(58.6–63.8)†††	(69.1–73.8)
Delaware	294	91.4	94.5	84.2	83.7	81.7	76.3	55.9	70.3
		(86.9–94.9)	(91.0–97.0)	(79.1–88.7)	(77.6–88.4)	(74.8–87.6)†††	(68.9–82.4)	(48.6–63.5)†††	(63.4–76.9)
District of Columbia	526	87.4	86.3	70.3	80.1	73.1	69.4	61.1	62.5
		(80.7–92.6)	(79.0–92.0)	(62.8–77.5)	(73.7–85.2)	(62.9–82.5)	(61.4–76.4)	(53.7–68.7)	(55.0–70.1)
Maryland	793	95.2	95.1	84.1	81.1	79.2	83.2	62.8	72.8
		(92.5–97.2)	(92.2–97.2)	(79.4–88.2)	(76.7–84.8)	(72.9–84.9)	(79.2–86.6)	(57.8–67.9)	(67.8–77.5)
Pennsylvania	1,027	89.7	92.0	84.0	84.1	84.5	79.9	62.2	72.2
		(86.8–92.2)	(89.4–94.2)	(80.6–87.2)	(80.4–87.2)	(77.1–90.6)	(76.2–83.2)	(57.8–66.7)†††	(68.0–76.3)
Philadelphia	480	91.7	91.4	82.4	81.3	80.7	75.3	66.4	72.7
		(87.6–94.9)	(87.7–94.3)	(76.8–87.3)	(74.9–86.3)	(71.7–88.4)	(69.3–80.5)	(60.3–72.4)	(66.6–78.5)
Pennsylvania, excluding Philadelphia	547	89.3	92.1	84.4	84.5	85.2	80.7	61.5	72.1
		(86.0–92.1)	(89.1–94.6)	(80.4–87.9)	(80.3–88.0)	(76.5–92.0)	(76.5–84.4)	(56.4–66.6)†††	(67.3–76.8)
Virginia	691	91.2	92.4	79.1	77.3	81.4	81.0	61.7	70.4
		(88.1–93.8)	(89.4–94.8)	(74.6–83.3)	(72.0–81.8)	(75.6–86.6)	(76.8–84.6)	(56.5–66.9)†††	(65.7–74.9)
West Virginia	459	94.5	95.5	83.9	80.7	88.4	79.4	48.0	71.4
		(91.8–96.5)§§§	(93.1–97.2)§§§	(79.5–87.8)§§§	(76.1–84.6)	(80.0–94.4)§§§	(74.9–83.2)§§§	(42.6–53.7)	(66.3–76.2)§§§
HHS Region 4, total	4,226	91.0	92.8	80.6	76.3	77.1	73.4	42.2	66.9
		(89.7–92.2)	(91.6–93.9)	(78.6–82.5)	(74.2–78.3)†††	(74.0–80.0)	(71.3–75.5)	(39.9–44.6)†††	(64.7–69.2)
Alabama	454	89.1	88.3	80.0	78.2	75.8	67.6	32.2	67.2
		(84.5–92.8)†††	(83.5–92.2)†††	(74.4–85.1)	(72.6–83.0)	(68.9–82.2)	(60.9–73.7)†††	(26.9–38.2)	(60.9–73.4)
Florida	636	92.0	93.6	81.9	74.7	75.4	74.1	39.8	72.5
		(89.1–94.4)	(90.7–95.9)	(77.5–86.0)	(69.9–79.1)	(68.1–82.1)	(69.2–78.5)	(34.6–45.5)	(67.7–77.2)
Georgia	569	87.4	91.9	76.2	77.9	80.1	74.9	41.5	58.7
		(82.9–91.2)	(88.3–94.8)	(70.5–81.5)	(72.7–82.3)	(73.1–86.3)	(69.6–79.6)	(36.1–47.5)	(52.7–64.8)†††
Kentucky	519	90.3	91.5	79.5	78.4	81.7	74.5	43.9	66.3
		(86.3–93.5)	(87.3–94.8)	(74.2–84.4)	(73.2–82.8)	(71.8–89.7)	(69.3–79.1)	(38.7–49.4)	(60.8–71.6)
Mississippi	428	88.4	88.3	77.2	79.2	56.0	61.2	25.2	64.4
		(81.5–93.6)	(81.8–93.3)	(69.9–83.8)	(72.4–84.6)	(46.5–65.9)	(53.8–68.2)	(20.1–31.4)†††	(57.0–71.8)
North Carolina	642	94.4	95.1	82.0	76.6	76.6	76.6	50.2	67.1
		(92.3–96.1)	(92.5–97.0)	(77.8–85.9)	(70.9–81.4)†††	(70.2–82.5)	(70.8–81.4)	(45.0–55.7)†††	(61.7–72.4)†††
South Carolina	460	90.8	92.8	84.0	79.5	79.4	79.8	40.0	68.0
		(87.0–93.8)	(89.7–95.2)	(79.3–88.2)	(71.8–85.4)	(71.2–86.6)	(74.4–84.4)	(33.5–47.2)	(62.2–73.7)

See table footnotes on the next page.

TABLE 3. (Continued) Estimated vaccination coverage by age 24 months* among children born during 2021–2022,[†] by selected vaccines and doses, overall and by area[§] — National Immunization Survey-Child, United States, 2022–2024

Area	No.	Vaccine coverage, % (95% CI)							Combined 7-vaccine series***
		MMR [¶] (≥1 dose)	Poliovirus (≥3 doses)	DTaP** (≥4 doses)	HepB ^{††} (birth dose)	HepA (≥2 doses by age 35 mos)	Rotavirus ^{§§}	Influenza ^{¶¶} (≥2 doses)	
Tennessee	518	91.6 (88.5–94.2)	94.6 (92.2–96.4)	81.1 (76.1–85.6)	72.0 (66.4–76.9)	83.1 (75.5–89.5)	68.5 (62.4–74.0)	52.4 (46.7–58.4)	64.0 (58.4–69.7)
HHS Region 5, total	3,532	92.0 (90.6–93.2)	92.5 (91.2–93.7)	83.7 (81.9–85.5)	82.7 (80.8–84.4)	80.7 (77.9–83.3)	78.0 (75.9–79.9)	58.4 (56.1–60.7)†††	72.7 (70.6–74.7)§§§
Illinois	883	93.0 (90.2–95.1)§§§	94.4 (91.9–96.3)	81.1 (77.3–84.7)	80.0 (76.3–83.2)	80.6 (74.9–85.6)	76.0 (72.0–79.6)	61.1 (56.8–65.4)	68.7 (64.5–72.7)
Chicago	247	92.9 (87.3–96.6)	93.9 (89.0–97.1)	81.6 (73.9–88.2)	78.8 (69.8–85.7)	84.9 (76.0–91.8)	78.3 (69.5–85.1)	63.8 (55.3–72.3)	73.0 (64.9–80.5)
Illinois, excluding Chicago	636	93.0 (89.8–95.5)	94.5 (91.5–96.7)	81.0 (76.5–85.1)	80.3 (76.3–83.8)	79.6 (72.8–85.6)	75.4 (70.7–79.5)	60.3 (55.3–65.3)	67.5 (62.7–72.2)
Indiana	351	90.8 (86.5–94.1)	90.1 (85.5–93.7)	82.0 (76.7–86.7)	81.0 (75.0–85.7)	79.8 (72.5–86.2)	78.9 (73.1–83.7)	51.5 (44.9–58.5)	74.3 (68.1–80.0)
Michigan	718	92.4 (88.6–95.3)	92.3 (88.9–95.0)	82.9 (77.9–87.4)	80.7 (75.0–85.3)	83.7 (76.0–90.0)	74.7 (68.8–79.7)	57.7 (52.1–63.4)†††	73.6 (68.5–78.4)
Minnesota	444	91.3 (87.4–94.4)	93.4 (90.2–95.9)	87.5 (83.1–91.2)	86.6 (82.5–89.9)§§§	78.6 (71.2–85.1)	81.4 (76.4–85.5)	68.4 (62.6–74.1)	72.0 (66.5–77.3)
Ohio	655	93.8 (91.1–95.9)	92.5 (89.4–94.9)	85.4 (81.3–89.1)	84.4 (80.3–87.7)	77.5 (71.1–83.3)	79.1 (74.6–83.1)	52.9 (47.7–58.3)†††	73.2 (68.4–77.7)
Wisconsin	481	87.5 (82.2–91.9)	91.4 (87.9–94.1)	85.1 (80.8–88.9)	86.2 (81.0–90.1)	83.9 (76.6–89.9)	80.3 (73.3–85.8)	64.0 (57.9–70.1)	77.0 (71.4–82.2)§§§
HHS Region 6, total	3,347	91.0 (89.2–92.7)	91.3 (89.5–93.0)	79.5 (76.8–82.1)	79.3 (76.5–81.8)	78.9 (74.2–83.3)	69.7 (66.5–72.7)†††	44.9 (41.7–48.3)†††	64.9 (61.8–68.0)
Arkansas	456	89.1 (84.6–92.7)	91.2 (87.1–94.5)	77.5 (71.9–82.7)	88.0 (83.7–91.4)§§§	76.6 (69.5–83.1)	74.6 (68.7–79.6)	36.6 (31.1–42.8)†††	65.5 (59.5–71.5)
Louisiana	642	90.8 (86.5–94.2)	94.1 (90.4–96.7)	80.3 (74.6–85.4)	78.0 (71.9–83.1)	75.9 (68.6–82.7)	75.9 (70.2–80.8)	34.7 (29.5–40.6)†††	68.2 (62.1–74.3)
New Mexico	538	90.7 (87.4–93.4)	92.1 (89.2–94.5)	79.3 (74.3–83.9)	78.7 (73.4–83.1)	73.7 (66.6–80.3)†††	78.7 (73.9–82.9)	51.1 (45.4–57.1)†††	68.7 (63.3–73.9)†††
Oklahoma	356	90.5 (86.1–94.0)	88.5 (83.1–92.8)	74.0 (67.7–80.0)	77.2 (71.2–82.3)	87.4 (78.8–93.7)§§§	66.4 (59.5–72.7)	39.3 (33.3–46.0)†††	61.7 (55.0–68.4)
Texas	1,355	91.3 (88.8–93.4)	91.3 (88.8–93.4)	80.3 (76.7–83.7)	80.3 (75.2–82.3)	79.0 (72.2–84.3)	78.5 (64.1–72.3)†††	68.3 (43.1–52.0)	64.6 (60.4–68.8)
Bexar County	410	93.2 (90.2–95.6)§§§	90.9 (86.1–94.5)	81.6 (76.1–86.5)§§§	75.4 (69.0–80.9)	80.2 (72.2–87.1)	70.4 (63.5–76.5)	52.0 (45.6–58.8)	65.2 (58.7–71.6)
Houston	343	88.3 (83.3–92.4)	89.1 (84.1–93.1)	75.1 (68.6–81.2)	78.7 (73.0–83.6)	78.7 (72.2–85.6)	69.4 (62.5–75.4)	45.8 (39.5–52.7)†††	61.0 (54.2–67.9)
Texas, excluding Bexar County and Houston	602	91.6 (88.6–94.0)	91.6 (88.6–94.1)	81.0 (76.6–85.0)	79.3 (74.7–83.2)	78.4 (70.6–85.2)	68.0 (62.9–72.8)†††	47.3 (42.1–52.9)	65.0 (60.0–70.0)
HHS Region 7, total	2,049	92.9 (91.4–94.3)§§§	93.3 (91.8–94.6)	81.5 (79.0–84.0)	82.5 (80.3–84.5)	80.0 (76.0–83.6)	78.3 (75.7–80.6)	54.0 (51.1–57.0)†††	69.6 (66.8–72.4)
Iowa	454	95.0 (92.1–97.1)	96.7 (94.5–98.2)	86.0 (81.4–90.0)	83.6 (79.0–87.4)	73.5 (65.3–81.1)	76.7 (71.3–81.3)	48.2 (42.5–54.2)	76.8 (71.6–81.6)
Kansas	610	89.9 (86.6–92.6)	89.2 (85.8–92.1)	78.0 (73.2–82.5)	78.2 (73.7–82.1)	81.4 (75.2–86.8)	70.8 (65.7–75.3)†††	45.3 (40.1–50.7)†††	65.8 (60.6–71.0)
Missouri	581	93.0 (90.1–95.3)§§§	93.3 (90.5–95.5)	80.1 (75.2–84.6)	83.8 (79.8–87.1)	82.8 (75.7–88.8)	81.7 (77.0–85.6)§§§	57.5 (52.2–62.9)	69.8 (64.6–74.8)
Nebraska	404	94.0 (90.6–96.6)	94.1 (91.2–96.3)	83.9 (79.1–88.1)	83.3 (78.2–87.4)	79.5 (72.8–85.5)	82.2 (77.0–86.4)	65.8 (60.0–71.5)†††	63.7 (57.9–69.5)
HHS Region 8, total	2,604	90.0 (88.1–91.7)	92.4 (90.6–93.9)	80.1 (77.4–82.6)	82.4 (80.1–84.5)	82.8 (79.1–86.1)	76.7 (74.1–79.2)	58.4 (55.3–61.5)†††	69.5 (66.6–72.4)
Colorado	479	90.2 (86.9–93.0)	92.2 (88.8–94.8)	79.7 (74.6–84.3)	82.0 (77.8–85.6)	82.9 (74.9–89.5)	78.6 (74.0–82.5)	64.8 (59.4–70.2)†††	69.0 (63.7–74.2)
Montana	373	87.0 (81.9–91.3)	91.7 (88.1–94.6)	74.7 (68.8–80.3)	79.3 (74.6–83.4)	71.5 (63.6–78.9)	68.7 (62.5–74.3)	47.6 (41.8–53.7)†††	67.1 (61.0–73.0)
North Dakota	384	88.3 (83.1–92.5)	90.7 (86.6–93.9)	79.6 (73.4–85.2)	85.1 (79.9–89.0)	75.0 (66.9–82.4)†††	77.6 (72.0–82.5)	61.6 (55.1–68.2)†††	69.1 (62.7–75.3)
South Dakota	424	92.2 (88.7–95.0)	93.0 (89.6–95.5)	85.7 (79.3–91.6)	85.7 (78.5–90.7)	81.7 (71.5–89.9)	75.0 (68.3–80.7)	57.5 (50.7–64.6)†††	64.2 (57.4–71.0)

See table footnotes on the next page.

TABLE 3. (Continued) Estimated vaccination coverage by age 24 months* among children born during 2021–2022,† by selected vaccines and doses, overall and by area§ — National Immunization Survey-Child, United States, 2022–2024

Area	No.	Vaccine coverage, % (95% CI)							
		MMR¶ (≥1 dose)	Poliovirus (≥3 doses)	DTaP** (≥4 doses)	HepB†† (birth dose)	HepA (≥2 doses by age 35 mos)	Rotavirus§§ (≥2 doses)	Influenza¶¶ (≥2 doses)	Combined 7-vaccine series***
Utah	481	90.9 (87.3–93.8)	93.5 (90.1–96.1)	83.4 (78.7–87.6)	83.2 (78.6–86.9)	89.8 (84.3–94.1)§§§	77.1 (71.6–81.8)	53.3 (47.6–59.3)†††	73.0 (67.5–78.2)
Wyoming	463	87.2 (82.8–90.9)	89.4 (85.3–92.8)	75.5 (70.0–80.7)	76.9 (71.3–81.6)	63.6 (56.9–70.2)	73.3 (67.6–78.3)	48.4 (42.6–54.5)†††	65.1 (59.4–70.8)
HHS Region 9, total	1,958	87.6 (84.3–90.6)	90.5 (87.6–93.0)	75.8 (71.7–79.7)	77.1 (72.9–80.8)	78.2 (72.7–83.3)	68.6 (64.1–72.8)	56.0 (51.7–60.4)†††	63.7 (59.5–68.0)
Arizona	438	87.8 (82.9–91.9)	94.4 (91.2–96.8)§§§	78.4 (72.0–84.2)	83.5 (77.4–88.2)	77.9 (69.9–85.0)	76.7 (70.3–82.0)	51.8 (45.3–58.7)	69.0 (62.6–75.2)
California	590	87.3 (83.0–90.9)	89.5 (85.7–92.6)	74.7 (69.6–79.6)	75.4 (70.0–80.1)	77.9 (70.9–84.2)	66.4 (60.6–71.7)	57.8 (52.3–63.4)†††	62.1 (56.7–67.6)
Hawaii	378	88.5 (84.0–92.3)	91.9 (88.6–94.6)	82.4 (76.5–87.5)	86.2 (81.3–90.0)	78.9 (69.2–87.2)	76.1 (70.4–80.9)	60.8 (54.2–67.4)	70.8 (64.4–76.8)
Nevada	552	92.1 (88.9–94.7)§§§	93.9 (91.4–95.9)	78.6 (73.2–83.5)	78.6 (73.0–83.2)	84.2 (75.8–90.9)§§§	73.2 (67.9–77.8)	41.9 (36.2–48.0)†††	67.3 (61.5–72.9)
HHS Region 10, total	1,843	92.4 (90.7–93.9)§§§	92.4 (90.6–93.9)	81.8 (79.2–84.3)	80.1 (77.3–82.6)	79.1 (75.1–83.0)	75.1 (72.2–77.7)	60.9 (57.8–64.1)†††	69.0 (65.9–71.9)
Alaska	405	83.0 (75.5–89.2)	83.7 (76.2–89.9)	66.4 (58.6–74.2)	75.9 (69.0–81.7)	69.3 (60.0–78.2)	66.6 (58.6–73.8)	43.3 (36.6–50.6)†††	53.0 (45.5–60.9)
Idaho	426	90.6 (87.0–93.6)	89.4 (85.0–93.0)	79.0 (73.9–83.7)	78.3 (73.2–82.6)	80.4 (72.2–87.4)	74.7 (69.0–79.6)	49.9 (44.2–55.9)†††	72.1 (66.7–77.2)
Oregon	407	92.7 (89.7–95.1)	92.5 (89.3–95.0)	80.9 (76.1–85.4)	82.9 (78.3–86.8)	77.8 (71.2–83.7)	73.7 (68.2–78.5)	61.4 (55.9–67.0)	65.4 (59.9–70.9)
Washington	605	93.5 (90.7–95.7)	93.9 (91.3–96.0)	84.4 (80.4–88.0)	79.6 (75.0–83.6)	80.4 (73.6–86.4)	76.7 (72.3–80.6)	65.5 (60.6–70.3)†††	71.5 (66.8–76.0)
Range of column values, states	NA	83.0–97.4	83.7–97.5	66.4–90.5	72.0–88.9	56.0–94.3	61.1–83.9	25.2–78.3	53.0–82.5
Territory****									
Guam	117	—¶¶¶	—¶¶¶	—¶¶¶	84.7 (72.8–92.0)	—¶¶¶	—¶¶¶	—¶¶¶	—¶¶¶
Puerto Rico	523	77.5 (72.2–82.5)§§§	80.1 (74.9–84.9)	64.9 (58.7–71.0)§§§	73.7 (67.8–78.8)	—¶¶¶	59.7 (53.1–66.0)	16.8 (12.3–22.9)	52.4 (45.7–59.3)§§§

Abbreviations: DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; HHS = U.S. Department of Health and Human Services; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; NA = not applicable; PCV = pneumococcal conjugate vaccine.

* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by age 35 months. For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥2 HepA doses).

† Data for the 2021 birth year are from survey years 2022, 2023, and 2024; data for the 2022 birth year are considered preliminary and are from survey years 2023 and 2024 (2025 data are not yet available).

§ [HHS Regional Offices | HHS.gov](https://www.hhs.gov/region)

¶ Includes children who might have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.

** Includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

†† One dose HepB administered from birth through age 3 days.

§§ Includes ≥2 doses of Rotarix monovalent rotavirus vaccine, or ≥3 doses of RotaTeq pentavalent rotavirus vaccine. (If any dose is RotaTeq or unknown, the recommendation defaults to the 3-dose series.) The maximum age for the final rotavirus dose is 8 months, 0 days.

¶¶ Doses must be ≥24 days apart (4 weeks with a 4-day grace period); doses could have been received during two influenza seasons.

*** The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of varicella vaccine, and ≥4 doses of PCV. Coverage estimates for vaccines not included in this table are available online. [Vaccination Coverage among Young Children \(0 – 35 Months\) | ChildVaxView | CDC](https://www.cdc.gov/vaccines/imz/childvaxview/)

††† Statistically significant decrease in estimated coverage compared with children born during 2019–2020 (p<0.05).

§§§ Statistically significant increase in estimated coverage compared with children born in 2019–2020 (p<0.05).

¶¶¶ Estimate not available because the unweighted sample size for the denominator was <30, or 95% CI half-width / estimate >0.588, or 95% CI half-width was ≥10.

**** Sample size was too small to calculate reliable coverage estimates for the U.S. Virgin Islands, because data were not collected there in 2022 and 2024.

2010–11 (6), and 280 pediatric deaths caused by influenza were reported, exceeding the highest number reported during a nonpandemic season since pediatric influenza deaths became reportable in 2004; 89% of those deaths occurred in children who were not fully vaccinated against influenza (7).

Differences in vaccination coverage by sociodemographic characteristics such as race and ethnicity, poverty status, MSA status, health insurance status, and eligibility for the VFC program persist, all of which have been documented in previous studies (8–10). VFC is designed to ensure that all

children have access to vaccines, regardless of their family's ability to pay. Growing a robust network of VFC-enrolled providers and ensuring the program reaches eligible children are essential to guaranteeing that all children have access to vaccination services.

Limitations

The findings in this report are subject to at least three limitations. First, the household response rates (22%–27% during survey years 2020–2024) and the availability of adequate provider data for only approximately one half of those with completed household interviews during these survey years could lead to selection bias that was not completely eliminated by the use of survey weighting adjustments. Without adequate information about study nonparticipants, the direction of such bias is unknown. Second, both the sampling procedure and the collection of data by household interview rely on respondents having cellular telephones; omission of households without cellular telephones could also be a source of selection bias, although the effect would likely be small: according to a [2025 Pew Research Center survey](#), 98% of adults in the United States own a cellular telephone. Finally, vaccination histories could be incomplete if not all providers were identified by interview respondents or if some providers did not respond to requests for vaccination information. Previous assessments of total survey error in NIS-Child have indicated that vaccination coverage is underestimated by up to 9 percentage points for certain vaccines. The 2024 total survey error estimates were similar to those from previous years for the vaccines assessed (NORC at the University of Chicago, CDC, unpublished data, 2025).

Implications for Public Health Practice

Vaccines have substantially reduced severe illness, hospitalization, and death and have saved approximately \$2.7 trillion in societal costs (1). Although national vaccination coverage remained stable for most vaccines, lower coverage among certain population subgroups and in some jurisdictions is creating an increased risk for outbreaks of vaccine-preventable diseases. During 2025, a total of 2,144 confirmed measles cases were reported in the United States, the largest number of annual cases since [measles was declared eliminated in 2000](#). Among these cases, 93% occurred in persons who were not vaccinated against measles or whose vaccination status was unknown. The preliminary number of [reported pertussis cases in 2024](#) was higher than that reported in 2019, before the COVID-19 pandemic. Because national and state data might obscure what is happening locally, state and local health departments are encouraged to analyze data from their immunization information systems to identify opportunities for increased attention and intervention.

Some of the strategies for helping parents make informed decisions and increasing vaccination coverage include strong, evidence-based provider recommendations, development of targeted messages from credible and trusted sources, and increasing participation in the VFC program (10). In addition, the Community Preventive Services Task Force recommends several other interventions to increase vaccination, including standing orders for vaccination, reminders from health care providers, immunization information systems, and vaccination programs in organized child care centers and in Special Supplemental Nutrition Program for Women, Infants, and Children settings. ([The Community Guide | CDC](#)). Additional evaluation of the behavioral and social drivers of vaccination can be helpful for the design of targeted interventions to engage with families about the importance of routine childhood vaccinations and their role in supporting children's health (4,5). Interventions such as these can increase vaccination coverage, reverse declines in vaccination coverage associated with the COVID-19 pandemic, and help protect all children from the morbidity and mortality associated with vaccine-preventable diseases.

Corresponding author: Holly A. Hill, hhill@cdc.gov.

¹Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

References

- Zhou F, Jatlaoui TC, Leidner AJ, et al. Health and economic benefits of routine childhood immunizations in the era of the Vaccines for Children program—United States, 1994–2023. *MMWR Morb Mortal Wkly Rep* 2024;73:682–5. PMID:39116024 <https://doi.org/10.15585/mmwr.mm7331a2>
- Issa AN, Wodi AP, Moser CA, Cineas S. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2025. *MMWR Morb Mortal Wkly Rep* 2025;74:26–9. PMID:39819853 <https://doi.org/10.15585/mmwr.mm7402a2>
- Kolasa MS, Tsai Y, Xu J, Fenlon N, Schillie S. Hepatitis B surface antigen testing among pregnant women, United States 2014. *Pediatr Infect Dis J* 2017;36:e175–80. PMID:28030527 <https://doi.org/10.1097/INF.0000000000001516>
- Kahn KE, Santibanez TA, Jain A, Zhou T, Black CL. Parental reasons for non-receipt of influenza vaccination among children 6 months-17 years and changes over time, 2015-2024. *Vaccine* 2025;61:127415. PMID:40602343 <https://doi.org/10.1016/j.vaccine.2025.127415>
- Santibanez TA, Black CL, Zhou T, Srivastav A, Singleton JA. Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines. *Vaccine* 2024;42:126139. PMID:39019662 <https://doi.org/10.1016/j.vaccine.2024.07.040>
- O'Halloran A, Habeck JW, Gilmer M, et al. Influenza-associated hospitalizations during a high severity season—Influenza Hospitalization Surveillance Network, United States, 2024–25 influenza season. *MMWR Morb Mortal Wkly Rep* 2025;74:529–37. PMID:40934142 <https://doi.org/10.15585/mmwr.mm7434a1>

7. Reinhart K, Huang S, Kniss K, Reed C, Budd A. Influenza-associated pediatric deaths—United States, 2024–25 influenza season. *MMWR Morb Mortal Wkly Rep* 2025;74:565–9. PMID:40996933 <https://doi.org/10.15585/mmwr.mm7436a2>
8. Hill HA, Yankey D, Elam-Evans LD, et al. Decline in vaccination coverage by age 24 months and vaccination inequities among children born in 2020 and 2021—National Immunization Survey-Child, United States, 2021–2023. *MMWR Morb Mortal Wkly Rep* 2024;73:844–53. PMID:39325676 <https://doi.org/10.15585/mmwr.mm7338a3>
9. Valier MR, Yankey D, Elam-Evans LD, et al. Vital signs: trends and disparities in childhood vaccination coverage by Vaccines for Children Program eligibility—National Immunization Survey-Child, United States, 2012–2022. *MMWR Morb Mortal Wkly Rep* 2024;73:722–30. PMID:39173180 <https://doi.org/10.15585/mmwr.mm7333e1>
10. Martinez ML, Coles S. Addressing immunization health disparities. *Prim Care* 2020;47:483–95. PMID:32718445 <https://doi.org/10.1016/j.pop.2020.05.004>

Morbidity and Mortality Weekly Report

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the U.S. Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR* at <https://www.cdc.gov/mmwr/index.html>.

Readers who have difficulty accessing this PDF file may access the HTML file at <https://www.cdc.gov/mmwr/index2026.html>. Address all inquiries about the *MMWR* Series to Editor-in-Chief, *MMWR* Series, Mailstop V25-5, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027 or to mmwrq@cdc.gov.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

MMWR and *Morbidity and Mortality Weekly Report* are service marks of the U.S. Department of Health and Human Services.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

ISSN: 0149-2195 (Print)